Published On: Fri, May 19th, 2017

New Analyst Ratings On LivaNova PLC (NASDAQ:LIVN)


Recently stock market analysts have updated their consensus ratings on shares of LivaNova PLC (NASDAQ:LIVN).

Most recent broker ratings

11/03/2016 – LivaNova PLC had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 54 price target on the stock.

08/31/2016 – LivaNova PLC had its “hold” rating reiterated by analysts at WBB Securities. They now have a USD 60 price target on the stock.

08/04/2016 – LivaNova PLC had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 70 price target on the stock.

02/29/2016 – LivaNova PLC had its “hold” rating reiterated by analysts at Kepler Cheuvreux. They now have a USD 66 price target on the stock.

11/25/2015 – LivaNova PLC had its “hold” rating reiterated by analysts at BTIG Research.

10/21/2015 – Berenberg Bank began new coverage on LivaNova PLC giving the company a “buy” rating. They now have a USD 80 price target on the stock.

LivaNova PLC has a 50 day moving average of 53.48 and a 200 day moving average of 48.76. The stock’s market capitalization is 2.83B, it has a 52-week low of 40.83 and a 52-week high of 63.21.

The share price of the company (NASDAQ:LIVN) was down -0.49% during the last trading session, with a high of 59.58 and the volume of LivaNova PLC shares traded was 697366.

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.